TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03813381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie and protein restriction diet
Description: Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food.~Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session.~Each patient in the IA will be involved in at least three 4-hour cooking classes.~Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention.
Study: NCT02710942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPHERE
Study: NCT04418908

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetrorelix acetate, 0.25 mg/day
Description: All participants self-administered GnRHant daily between the baseline and follow-up visits (cetrorelix acetate, 0.25 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release
Description: Active estradiol transdermal patch.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Placebo patch designed to match active Climara patches.
Study: NCT03845842

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Volitional help sheet
Description: Participants are asked to choose from a list of strategies for avoiding cannabis use.
Study: NCT02710942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISM
Study: NCT03118830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrorelix
Description: Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Follicle Stimulating Hormone
Description: Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Follicle Stimulating Hormone
Description: Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
Study: NCT02421601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Condoliase
Description: 1.25 U, intradiscal injection, one time
Study: NCT01662947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117
Description: Systolic, Diastolic pressure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2
Description: Systolic, Diastolic pressure
Study: NCT01873690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Once, 400 mg IV
Study: NCT00559572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time and attention control group sessions
Description: Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
Study: NCT01873690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% Dextrose in water
Study: NCT00996346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan&Temsirolimus:Arm1, Level 1
Description: Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan&Temsirolimus:Arm 1, Level 2
Description: Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan&Temsirolimus:Arm 2, Level 1
Description: Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
Study: NCT03845842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Description: Participants are asked to choose from a list of strategies for avoiding cannabis use.
Study: NCT03619135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: The Buzzy is a reusable device that applies vibration to the skin surface to override the body's gate control pain pathway. It has been used effectively to reduce the discomfort of intravenous cannulation (IV placement) in pediatric patients. Also, it has been utilized to reduce the discomfort of injections in pediatric and adult patients. We are preforming this study to evaluate the effectiveness of the Buzzy in reducing the discomfort associated with intravenous cannluation (IV placement) in adults.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No use of the Buzzy (standard IV access techniques)
Study: NCT02108665

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiographic hysterosalpingography

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiographic hysterosalpingography

Intervention type: RADIATION
Group type: OTHER
Intervention: Magnetic resonance imaging hysterosalpingography

Intervention type: RADIATION
Group type: OTHER
Intervention: Magnetic resonance imaging hysterosalpingography
Study: NCT01884415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV vaccine
Description: Patients receive a second cycle of vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBV vaccine
Description: Patients receive vaccination according to the guidelines.
Study: NCT03613935

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 2
Description: Comparison with products 1, 3, and 4
Study: NCT01475162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
Study: NCT03631420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Derived-Mesenchymal Stem Cells
Description: Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg
Study: NCT03613935

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 2
Description: Comparison with products 1, 3, and 4

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 3
Description: Comparison with products 1, 2, and 4

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 3
Description: Comparison with products 1, 2, and 4

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 3
Description: Comparison with products 1, 2, and 4

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 4
Description: Comparison with products 1, 2, and 3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 4
Description: Comparison with products 1, 2, and 3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 4
Description: Comparison with products 1, 2, and 3
Study: NCT00654173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study: NCT00664742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin XL®
Description: Fluvastatin extended release 80 mg
Study: NCT01817894

Intervention type: DRUG
Group type: OTHER
Intervention: Eflornithine cream 11.5 w/w %
Description: Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
Study: NCT00729547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: enhance relative activity level of left frontal activity

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychotherapy placebo
Description: These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder.
Study: NCT05018741

Intervention type: PROCEDURE
Intervention: liver transplantation
Description: liver transplantation for chronic liver disease or acute liver failure
Study: NCT00957333

Intervention type: OTHER
Intervention: ketamine
Study: NCT00635089

Intervention type: DRUG
Group type: OTHER
Intervention: reslizumab
Study: NCT03518346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Samsung VR Go (VR head set), Samsung S7 (phone), and programmed distraction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Books, movies, TV
Study: NCT04518163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Intravenous 1 gm tranexamic acid in 100 ml saline by slow infusion before skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to TA
Description: Intravenous 110 ml saline by slow infusion before skin incision

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bakri Balloon
Description: Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bakri Balloon
Description: Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
Study: NCT03997643

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy to all dissected areas
Description: Post operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Omit radiation to pN0 neck
Description: post operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck
Study: NCT00368121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab +/- Dexamethasone
Description: Cetuximab dosing schedule:~• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion~Dexamethasone dosing schedule:~• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.~Mode of administration: orally
Study: NCT02128945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F] - Fludarabine PET/CT
Description: \[18F\] - Fludarabine PET/CT before treatment
Study: NCT02602665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shallow catheter tip placement
Description: for shallow placement tip of catheter placed 1 vertebral body above to even with the carina

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep catheter tip placement
Description: deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
Study: NCT03218579

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic treatment
Description: 4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bacteriotherapy
Description: Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
Study: NCT02358915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FastStart neuromuscular electrical stimulator
Study: NCT03151928

Intervention type: DIAGNOSTIC_TEST
Intervention: BDMax Vaginal Panel
Description: The tests will be used to compare results between clinician diagnosis/routine care testing and the above interventions
Study: NCT01443663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Vaccine
Description: Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Vaccine
Description: Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Vaccine
Description: Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Vaccine
Description: Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
Study: NCT02290509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok Quadrivalent
Description: Intramuscular injection of study vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine (IIV4)
Description: Intramuscular injection of study vaccine
Study: NCT03040063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined endovascular approach (EVAR)
Description: 1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Heparin 70-80 IU/kg i.a.~5. implantation of peripheral stent graft VIABAHN~6. implantation of peripheral stent SUPERA into stent graft~7. insertion of strait flush catheter for local thrombolysis~8. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards~9. control angiography in 12 hrs or earlier according to clinical status and symptoms~10. repeated angiography in 24 hrs
Study: NCT01682811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Levulan surface application twice with microneedling
Description: Control or treatment lesions will be prepared with microneedling, painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 24 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1
Description: 2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 8 minutes to achieve a dose of 50 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2
Description: 2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 16 minutes to achieve a dose of 100 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3
Description: 2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 32 minutes to achieve a dose of 200 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
Study: NCT02443740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB118
Description: Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 3 mg, 30 mg, 200 mg, 800 mg and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB118
Description: Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB118
Description: Single dose (Maximum Tolerated Dose) of BIIB118 as extemporaneously prepared solution/suspension
Study: NCT01840306

Intervention type: OTHER
Intervention: Biomarker Analysis

Intervention type: OTHER
Intervention: Biomarker Analysis
Study: NCT01328522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191 (REGN88)
Description: Pharmaceutical form:solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191 (REGN88)
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study: NCT00641446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varicella zoster virus
Study: NCT02443987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous fluid
Description: 500ml infusion of 0.9% Sodium Chloride intravenously.
Study: NCT00420732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute-Lung Cancer Vaccine
Description: 300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations
Study: NCT02051556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy WSI
Description: Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy BSI
Description: Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy ST
Description: Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
Study: NCT02565940

Intervention type: OTHER
Intervention: biopsy
Study: NCT00202930

Intervention type: DRUG
Group type: OTHER
Intervention: anti-CD20 (Rituximab)
Description: 4 weekly doses of IV rituxan at 375 mg/m2 on days 1, 8, 15 and 22
Study: NCT01255137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg tab orally twice a day with food every 28 days
Study: NCT01443663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Vaccine
Description: Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
Study: NCT01789216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentinoids

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01950923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo standard robotic partial nephrectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo standard robotic partial nephrectomy
Study: NCT02013648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Study: NCT00825318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Description: Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
Study: NCT01762397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMK-S005
Study: NCT01113736

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloMEM™
Description: To investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients.